MRK, Daiichi's ADC Drug Gets FDA Breakthrough Tag for Ovarian Cancer

Key Takeaways MRK's R-DXd wins FDA Breakthrough status for certain platinum-resistant ovarian and related cancers.The designation was supported by data from ongoing REJOICE-Ovarian01 and phase I studies.This is the second Breakthrough Therapy win under MRK's collaboration with Daiichi Sankyo.Merck (MRK)  and its Japanese partner Daiichi Sankyo announced that the FDA has granted Breakthrough Therapy Designation ("BTD") to their investigational pipeline candidate, raludotatug deruxtecan (R-DXd). The regulator ...